BioLife Solutions (STU:BJX1) LT-Debt-to-Total-Asset : 0.04 (As of Mar. 2025)

View and export this data going back to 2017. Start your Free Trial

What is BioLife Solutions LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BioLife Solutions's long-term debt to total assests ratio for the quarter that ended in Mar. 2025 was 0.04.

BioLife Solutions's long-term debt to total assets ratio declined from Mar. 2024 (0.07) to Mar. 2025 (0.04). It may suggest that BioLife Solutions is progressively becoming less dependent on debt to grow their business.

BioLife Solutions LT-Debt-to-Total-Asset Historical Data

The historical data trend for BioLife Solutions's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions LT-Debt-to-Total-Asset Chart

BioLife Solutions Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.04

0.09

0.06

0.04

BioLife Solutions Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.07	0.06	0.06	0.04	0.04

BioLife Solutions LT-Debt-to-Total-Asset Calculation

BioLife Solutions's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	16.923	/	381.51
	=	0.04

BioLife Solutions's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (Q: Mar. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2025 )	/	Total Assets (Q: Mar. 2025 )
	=	13.564	/	365.505
	=	0.04

BioLife Solutions (STU:BJX1) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BioLife Solutions LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of BioLife Solutions's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLife Solutions Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (STU:BJX1) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

BLFS:USA

Address

3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021

Website

https://www.biolifesolutions.com

BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

BioLife Solutions Headlines

No Headlines